DESIGN, EXECUTION, AND MANAGEMENT OF MEDICAL DEVICE CLINICAL TRIALS

SALAH ABDEL-ALEEM



DESIGN, EXECUTION, AND MANAGEMENT OF MEDICAL DEVICE CLINICAL TRIALS

DESIGN, EXECUTION, AND MANAGEMENT OF MEDICAL DEVICE CLINICAL TRIALS

SALAH ABDEL-ALEEM



Copyright © 2009 by John Wiley & Sons, Inc. All rights reserved.

Published by John Wiley & Sons, Inc., Hoboken, New Jersey. Published simultaneously in Canada.

No part of this publication may be reproduced, stored in a retrieval system, or transmitted in any form or by any means, electronic, mechanical, photocopying, recording, scanning, or otherwise, except as permitted under Section 107 or 108 of the 1976 United States Copyright Act, without either the prior written permission of the Publisher, or authorization through payment of the appropriate per-copy fee to the Copyright Clearance Center, Inc., 222 Rosewood Drive, Danvers, MA 01923, (978) 750-8400, fax (978) 750-4470, or on the web at www.copyright.com. Requests to the Publisher for permission should be addressed to the Permissions Department, John Wiley & Sons, Inc., 111 River Street, Hoboken, NJ 07030, (201) 748-6011, fax (201) 748-6008, or online at http://www.wiley.com/go/permission.

Limit of Liability/Disclaimer of Warranty: While the publisher and author have used their best efforts in preparing this book, they make no representations or warranties with respect to the accuracy or completeness of the contents of this book and specifically disclaim any implied warranties of merchantability or fitness for a particular purpose. No warranty may be created or extended by sales representatives or written sales materials. The advice and strategies contained herein may not be suitable for your situation. You should consult with a professional where appropriate. Neither the publisher nor author shall be liable for any loss of profit or any other commercial damages, including but not limited to special, incidental, consequential, or other damages.

For general information on our other products and services or for technical support, please contact our Customer Care Department within the United States at (800) 762-2974, outside the United States at (317) 572-3993 or fax (317) 572-4002.

Wiley also publishes its books in a variety of electronic formats. Some content that appears in print may not be available in electronic formats. For more information about Wiley products, visit our web site at www.wiley.com.

Library of Congress Cataloging-in-Publication Data:

Abdel-aleem, Salah.

Design, execution, and management of medical device clinical trials / Salah Abdel-aleem. p.; cm.

Includes bibliographical references and index. ISBN 978-0-470-47426-6 (cloth)

1. Medical instruments and apparatus-Research. 2. Clinical trials. I. Title.

[DNLM: 1. Equipment and Supplies–standards. 2. Clinical Trials as Topic–methods. 3. Device Approval–standards. 4. Evaluation Studies as Topic. W 26 A135d 2009]

R856.4.A23 2009 610.28'4—dc22

2008049904

Printed in the United States of America.

10 9 8 7 6 5 4 3 2 1

Dedication

For my mother, Farha, my loving wife, Maro, and my sons Omar, Tarek, and Yussuf. Your support has been truly inspirational.

CONTENTS

List of Abbreviations		
Preface Acknowledgments		
	Key Clinical Study Tasks and Activities, 2 Discussion of Key Tasks and Activities, 3 Management of Key Clinical Tasks and Activities, 9 Example of the Spread Sheet for Managing Clinical Study Activities, 10 The Clinical Research Team, 10	
2	Development of Clinical Protocols, Case Report Forms, Clinical Standard Operating Procedures, Informed Consent Form, Study Regulatory Binder, Study Research Agreement, and Other Clinical Materials	15
	Clinical Protocol, 17 Case Report Forms (CRFs), 28 Example of the Case Report Form Template, 32 Informed Consent Form (ICF), 35 Instructions for Use of Device, 38	

Study Research Agreement, 40 Research Agreement Template, 43 Research Contract Challenges, 50 Clinical Forms and Certificates, 51 Clinical Standard Operating Procedures (SOPs), 54

3 Qualification/Selection of Study Investigators and Study Monitoring Visits

Qualification and Selection of Investigators, 64 Monitoring Visits, 67 Monitoring Reports, 73 Interim Monitoring Visit Report Template, 75

4 Adverse Events Definitions and Reporting Procedures 81

Adverse Event Definitions, 83 Policies, Regulations, and Guidelines Regarding Adverse Event Reporting, 84 Adverse Event Reporting Pathway, 84 Terms for Causality Assessment, 85 GAPS/Challenges in Adverse Event Reporting, 86 Adverse Event Reporting Time Periods (21 CFR 803), 88 Differences between the United States and Europe in Reporting Adverse Events, 88 Serious Adverse Event Narratives, 89 Classification of Adverse Events, 90 Special Requirement for Reporting Certain Adverse Events, 92 Case Example, 92 Mandatory Device Reporting for FDA-Approved Devices, 92

5 Statistical Analysis Plan (SAP) and Biostatistics in Clinical Research

Statistical Analysis Plan (SAP), 94 Selection of Study Endpoints, 97 Biostatistics in Clinical Research, 101

6 Final Clinical Study Report

Final Clinical Report's Outline, 114

113

93

63

Discussion of Sections in the Final Clinical Report, 116

7 Medical Device Regulations, Combination Product, Study Committees, and FDA-Sponsor Meetings

Medical Device Regulations, 129 Combination Products, 164 Study Committees, 168 FDA-Sponsor Meetings, 170 Registration of Clinical Trials, 174 Implementation of the HIPAA Privacy Rule in Clinical Research, 175 Institutional Review Boards (IRB), 180 FDA's Oversight of Clinical Trials (Bioresearch Monitoring), 191 Code of Federal Regulations of Medical Devices, 194

8 Design Issues in Medical Devices Studies

195

127

Design of the Clinical Trial, 196 Assumptions and Parameters of Clinical Trial Design, 196 Clinical Trials' Design Issues and Data Analysis Issues, 202 Use of Historic Controls as the Control Group in IDE Studies, 206 Summary of Recommendations When Using Historic Controls, 218

9 Investigator-Initiated Clinical Research

221

Definition and Examples of Investigator-Initiated Clinical Research, 222 Development, Conduct, and Management of Investigator-Initiated Clinical Research, 224 Regulation of Investigator-Initiated Clinical Research, 225 Required Infrastructure for Investigator-Initiated Clinical Research, 226 Clinical Research Sponsored by NIH, 227

10 Ethical Conduct for Human Research

229

The Nuremberg Code (1947), 230

x CONTENTS

World Medical Association—Declaration of Helsinki (1964–Present), 231 National Commission for the Protection of Human Subjects of Biomedical and Behavioral Research (1974), 231 The Belmont Report (1978), 232 Special Ethical Concerns in Clinical Research on Use of Placebo, 232

Glossary of Clinical Trial and Statistical Terms	235
References	249
Index	255

LIST OF ABBREVIATIONS

AE	Adverse event
ACE	Angiotensin converting enzyme
ANDA	Abbreviated new drug application
ARR	Absolute risk reduction
BMS	Bare metal stent
CBER	Center for Biologics Evaluation and Research (FDA)
CDHR	Center for Devices and Radiological Health (FDA)
CDER	Center for Drug Evaluation and Research (FDA)
CE marking	A mandatory European marking for certain product groups to indicate conformity with the essential health
	and safety requirements set out in European directives
CFR	Code of federal regulation
CMS	Centers for Medicare and Medicaid Services
CRA	Clinical research associate
CRFs	Case report forms
CRPAC	Clinical research policy analysis and coordination
CRO	Clinical research organization
CLI	Critical limb ischemia
DCFs	Data correction forms
DES	Drug eluting stent
DOB	Date of birth

xii LIST OF ABBREVIATIONS

DOD	Date of death
DSMB	Data safety monitoring board
EC	Ethics committee
ELA	Excimer laser atherectomy
FDA	Food and Drug Administration
FWA	Federal wide assurance
LACI	Laser angioplasty for critical limb ischemia
LOI	Letter of intent
GCP	Good clinical practice
GMDN	Global medical device nomenclature
HDE	Humanitarian device exemption
HIPAA	Health Insurance Portability Accountability Act
HUD	Humanitarian use device
ICF	Informed consent form
IDE	Investigational device exemption
IND	Investigational new drug
IRB	Institutional review board
NDA	New drug application
NIH	National Institute of Health
NSR	Nonsignificant risk
MACE	Major adverse cardiac events
MI	Myocardial infarction
OHRP	Office of Human Research Protection
OPC	Objective performance criteria
PAD	Peripheral artery disease
PI	Principal investigator
PMA	Premarket approval
PTA	Percutaneous transluminal angioplasty
RAS	Renin-angiotensin system
RRR	Relative risk reduction
SAE	Serious adverse event
SAP	Statistical analysis plan
SFA	Superficial femoral artery
SR	Significant risk
SOP	Standard operating procedures

SSNSocial security numberTASCTransAtlantic Inter-Societal ConsensusTLRTarget lesion revascularizationTVRTarget vessel revascularizationUADEUnanticipated adverse device effectWHCWeighted historic control